{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:15:29Z","timestamp":1761016529195,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":2511,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.seizure.2006.05.013","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T08:44:41Z","timestamp":1155113081000},"page":"434-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of levetiracetam in clinical practice: Results of the SKATE\u2122 trial from Belgium and The Netherlands"],"prefix":"10.1016","volume":"15","author":[{"given":"D.A.J.E.","family":"Lambrechts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sadzot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"van Paesschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"van Leusden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Carpay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Urbain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.J.M.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2006.05.013_bib1","unstructured":"World Health Organization. Epilepsy: aetiology, epidemiology and prognosis. WHO Fact Sheet No. 165. Revised February 2001."},{"key":"10.1016\/j.seizure.2006.05.013_bib2","unstructured":"Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. CPMP\/EWP\/566\/98 rev.1 (16 November 2000)."},{"key":"10.1016\/j.seizure.2006.05.013_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2006.05.013_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2001.00003.x","article-title":"Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?","volume":"42","author":"Klitgaard","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2006.05.013_bib5","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.seizure.2006.05.013_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(01)01884-5","article-title":"Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices","volume":"306","author":"Niespodziany l","year":"2001","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/j.seizure.2006.05.013_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2006.05.013_bib8","first-page":"471","article-title":"Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons","volume":"14","author":"\u00c4ngehagen","year":"2003","journal-title":"Neuropharmacology and Neurotoxicology"},{"key":"10.1016\/j.seizure.2006.05.013_bib9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.seizure.2006.05.013_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.seizure.2006.05.013_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","article-title":"Effect of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials","volume":"53","author":"Perucca","year":"2003","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.seizure.2006.05.013_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1059-1311(02)00292-3","article-title":"An open-label study of levetiracetam at individualised doses between 1000 and 3000mgday\u22121 in adult patients with refractory epilepsy","volume":"12","author":"Abou-Khalil","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2006.05.013_bib13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2006.05.013_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose response effect of levetiracetam 1000 and 2000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.seizure.2006.05.013_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.seizure.2006.05.013_bib16","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2006.05.013_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1167.2001.00007.x","article-title":"Efficacy of levetiracetam: a review of three pivotal clinical trials","volume":"42","author":"Privitera","year":"2001","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.seizure.2006.05.013_bib18","first-page":"177","article-title":"Dose-response relationship of levetiracetam","volume":"9","author":"Privitera","year":"2002","journal-title":"European Journal of Neurology"},{"issue":"Suppl. 9.","key":"10.1016\/j.seizure.2006.05.013_bib19","article-title":"Fast action of levetiracetam","volume":"44","author":"French","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2006.05.013_bib20","first-page":"426","article-title":"A new antiepileptic drug. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug","volume":"72","author":"Shorvon","year":"2002","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1016\/j.seizure.2006.05.013_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0920-1211(02)00247-4","article-title":"Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy","volume":"53","author":"Ben-Menachem","year":"2003","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.seizure.2006.05.013_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(03)00080-9","article-title":"The KEEPER\u2122 trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study","volume":"54","author":"Morrell","year":"2003","journal-title":"Epilepsy Research"},{"issue":"Suppl. 8","key":"10.1016\/j.seizure.2006.05.013_bib23","first-page":"153","article-title":"Skate trial interim analysis: confirmation of safety and efficacy of levetiracetam (Keppra\u00ae) as adjunctive therapy in patients with refractory epilepsy.","volume":"44","author":"Steinhoff","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2006.05.013_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2006.05.013_bib25","unstructured":"EMEA, Keppra\u00ae Summary of Product Characteristics. 2003."},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2006.05.013_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1528-1167.2001.00008.x","article-title":"Safety profile of levetiracetam","volume":"42","author":"Harden","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2006.05.013_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.seizure.2006.05.013_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults wit epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behavior"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131106001129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131106001129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:35:03Z","timestamp":1761010503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131106001129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1059131106001129"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2006.05.013","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of levetiracetam in clinical practice: Results of the SKATE\u2122 trial from Belgium and The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2006.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}